REGN240726C1020000
- 45.00
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
Regeneron Pharma Price Target Raised to $1200.00/Share From $1030.00 by TD Cowen
Regeneron Pharma Is Maintained at Buy by TD Cowen
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,200
Express News | Regeneron Pharmaceuticals Inc : TD Cowen Raises Target Price to $1,200 From $1,030
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,166
TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,030, Maintains Buy Rating
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
Regeneron Pharma Is Maintained at Neutral by Cantor Fitzgerald
HRMY or REGN: Which Is the Better Value Stock Right Now?
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $925
Express News | Regeneron Pharmaceuticals Inc : Jefferies Raises Target Price to $1,235 From $1,135
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,300 From $1,082, Outperform Rating Maintained
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,166
Express News | Regeneron Pharmaceuticals Inc : Piper Sandler Raises Target Price to $1,166 From $1,000